Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
| Author | |
|---|---|
| Abstract | :
Vedolizumab, an α4β7 integrin monoclonal antibody inhibiting gut lymphocyte trafficking, is an effective treatment for ulcerative colitis (UC). We evaluated the optimal position of vedolizumab in the UC treatment paradigm. |
| Year of Publication | :
2018
|
| Journal | :
Inflammatory bowel diseases
|
| Volume | :
24
|
| Issue | :
2
|
| Number of Pages | :
286-295
|
| Date Published | :
2018
|
| ISSN Number | :
1078-0998
|
| URL | :
https://academic.oup.com/ibdjournal/article-lookup/doi/10.1093/ibd/izx045
|
| DOI | :
10.1093/ibd/izx045
|
| Short Title | :
Inflamm Bowel Dis
|
| Download citation |